DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma
- 1 January 1995
- journal article
- Published by Wiley in British Journal of Urology
- Vol. 75 (1), 26-32
- https://doi.org/10.1111/j.1464-410x.1995.tb07227.x
Abstract
To evaluate whether DNA ploidy and immunohistochemistry performed in primary prostatic carcinoma specimens give predictive information on regional lymph node metastasis in addition to T category, histological grade and serum prostate specific antigen (PSA). Pre-treatment TURP specimens from 80 patients with prostatic carcinoma T0-T3/M0 disease were retrospectively evaluated by means of DNA ploidy and histological grade, and immunostaining for PSA, prostatic acid phosphatase (PAP), neuron-specific enolase (NSE) and p53 protein. Pelvic lymph node dissection was performed in all patients. Serum PSA was determined in 76 of the 80 patients before pelvic staging lymphadenectomy. Thirty-two (40%) of the 80 patients had pN+ disease. Thirty-six patients (46%) had serum PSA values below the upper reference limit (< or = 10 micrograms/L). By univariate analysis the pN category correlated with the serum PSA level (P < 0.001), histological grade (P < 0.001), tissue PSA (P < 0.001), tissue PAP (P < 0.04), T category (P < 0.005) and DNA ploidy (P < 0.02). Multivariate analysis revealed that the serum PSA level was the most powerful independent prognosticator, followed by the T category, tissue PAP and tissue PSA. Histological grade and DNA ploidy did not reach the level of significance in the multivariate analysis. These data suggest that tissue PAP and tissue PSA predict the pN status in patients with T0-T3/M0 prostate carcinoma, in addition to serum PSA and T category. Neuroendocrine differentiation and p53 protein seem to have no predictive ability.Keywords
This publication has 25 references indexed in Scilit:
- Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimensBritish Journal of Cancer, 1993
- Serum prostate-specific antigen: expanding its role as a measure of treatment response in patients with prostate cancer.Journal of Clinical Oncology, 1993
- Neuroendocrine differentiation in human prostatic carcinomaHuman Pathology, 1992
- Neuro‐endocrine Cells—A New Prognostic Parameter in Prostate CancerBritish Journal of Urology, 1991
- Monoclonal prostate-specific antigen in untreated prostate cancer. Relationship to clinical stage and gradeCancer, 1991
- Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinomaThe Prostate, 1991
- DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage gleason grade 4 and 5, and lymph node metastasesCancer, 1990
- Stage B Prostate AdenocarcinomaArchives of Surgery, 1990
- Prognostic Significance of Lymph Nodal Metastases in Prostate CancerJournal of Urology, 1989
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987